“Fresenius Kabi and Regeneron Reach Settlement”
Samcheondang Pharmaceutical announced that it has settled the U.S. patent dispute over its Eylea biosimilar and secured local sales rights.
On the 25th, Samcheondang Pharmaceutical stated in a shareholder notice that its U.S. partner, Fresenius Kabi, had finalized a patent dispute settlement with the originator company Regeneron on the 12th. Due to confidentiality provisions, the specific terms of the agreement cannot be disclosed, but the company explained that through this settlement it has secured the right to sell the Eylea biosimilar “Vizenfry (SCD411)” in the U.S. market.
In the shareholder notice, Samcheondang Pharmaceutical CEO Jeon Inseok said, “We have officially secured the sales rights in the U.S., which is the most important market,” adding, “We will proceed with our global expansion as planned without any setbacks.”
This settlement is also linked to the recent sharp rise in the company’s share price. Since the beginning of this year, Samcheondang Pharmaceutical’s share price has risen by more than 170%, which is seen as reflecting expectations for the global rollout of its Eylea biosimilar. In the market, analysts say that the resolution of the U.S. patent dispute has partially removed key commercialization-related uncertainties. However, since the terms of the settlement are not public, the specific launch timing and profit structure are expected to be disclosed at a later date.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
